Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Heinonen, Mikko	en_US
dc.date.accessioned	2012-06-07T20:38:50Z
dc.date.issued	2002	en_US
dc.identifier.citation	Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws (2002 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852181
dc.description.abstract	The purpose of this article is to highlight the main issues raised by the Food and Drug Administrationâ€™s (â€&oelig;FDAâ€) approval process relating to new drugs and the treatment of this process receives in the context of the Federal Securities Laws . The partial inspiration for this article has been the recent highly publicized case concerning ImClone Systems Incorporated â€“ a case, which well exemplifies both the connection between the valuation of a biotech/medical company and the FDAâ€™s approval process for new drugs, and also the huge effect of the approval process to the marketâ€™s valuation of the stock price.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	FDA	en
dc.subject	securities	en
dc.subject	disclosure	en
dc.subject	approval	en
dc.subject	ImClone	en
dc.title	Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T20:38:50Z